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Glucocorticoids such as prednisolone are commonly used in dogs but there is
sparse quantitative pharmacokinetic and pharmacodynamic information of this drug
in this species. The objective of this study was to quantitatively characterize the
concentration-effect relationship for prednisolone in dogs on neutrophil and lymphocyte
trafficking and cortisol suppression. Nine beagles, 2–12 years old and part of a
group for teaching/research were used in a 4-way crossover experiment including
two treatments, active or placebo, administered either per os (PO) or intravenously
(IV). Plasma was analyzed for prednisolone and cortisol using ultra-high performance
liquid chromatography – tandem mass spectrometry. Leucocyte counts were performed
in whole blood. Data was then analyzed by non-linear mixed effect modeling to
estimate pharmacokinetic and pharmacodynamic parameters. After administration of
prednisolone sodium succinate IV, the typical value (between subject variation) for total
body prednisolone clearance was 1,370 ml/h·kg (13.4%). The volumes of the central and
peripheral compartment were 2,300 ml/kg (10.7%) and 600 ml/kg (16.0%), respectively.
The terminal plasma half-life was 1.7 h. The prednisolone plasma concentration
producing 50% of the maximum response was 10 ng/mL (90.3%), 22.5 ng/ml (52.3%)
and 0.04 ng/mL (197.3%) for neutrophil, lymphocyte and cortisol response, respectively.
The administered dose (1 mg/kg) increased neutrophil and decreased lymphocyte
numbers but not over the entire dosage interval of 24 h, due to the short half-life. However,
glucocorticoids have a wide range of responses. An anti-inflammatory response due
to altered gene transcription might have a longer duration. Future studies on the
anti-inflammatory potency together with data presented are needed to optimize future
dosage recommendations in dogs.
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INTRODUCTION
Prednisolone is a glucocorticoid commonly used in dogs
for its anti-inflammatory and immune-suppressive effects.
Despite its wide use, sparse information is available about
the pharmacokinetics (PK) and pharmacodynamics (PD)
of prednisolone in dogs. More than 35 years ago, some
pharmacokinetic reports were published (1–4). More recently,
prednisolone concentration-time data have been made available
but without thorough PK-analyses (5, 6). The PK studies cited
above were performed on few dogs and since then technical
improvements have made the analytical techniques for drug
quantification in plasma more sensitive. A lower limit of
quantification (LOQ) makes it possible to accurately measure
drug concentrations for an extended time after administration.
This allows for an increased understanding of the disposition of
the drug during the terminal phase of the concentration-time
curve, better informing the value of the PK-parameters, and
the relationship between lower drug concentrations and effects.
An example is the improved understanding of dexamethasone
disposition in horses after improvements to the analytical
method (7, 8). The increased analytical sensitivity used by Soma
et al. (8) revealed a third compartment with considerably longer
terminal half-life than reported by Toutain et al. (7), which is
important to understand drug accumulation and duration of
cortisol suppression. In addition, modern personal computers
and software allows more sophisticated PK/PD analyses, so
called non-linear mixed effects models or population analyses
that not only model individual concentration time-courses
but also variability in the data (9). These models were first
used in data sets where a limited number of samples were
collected from a large number of subjects, but they are also
useful to analyse richer data sets from fewer individuals (10, 11).
In humans, there is information available about the potency
and efficacy of prednisolone (12, 13). In veterinary medicine,
this information is missing. Additional PK/PD information is
needed to identify appropriate starting doses and design better
clinical trials for future optimized dosage regimens. Hence, the
aim of this study was to characterize the dose-concentration-




The study was conducted in nine beagle dogs that were a
part of a group for teaching and research and accustomed
to handling and sampling (Table 1). The dogs were kept
in their home environment. Before each treatment, an
intravenous (IV) catheter was placed in the cephalic vein
for blood sampling. Before IV treatment an additional
IV catheter was placed in the saphenous vein and used
only to administer the prednisolone. The dogs were
housed in groups of two to four dogs for social and
welfare reasons.
TABLE 1 | Population characteristics, prednisolone doses and treatment order.











1 Female 12 14.5 14.5 15 BADC
2 Female 7 14.2 14.2 15 BADC
3 Female 10 15.1 15.1 15 BADC
4 Male 5 15.1 15.1 15 BADC
5 Male 7 14 14 15 BADC
6 Male 8 14.5 14.5 15 ABCD
7 Male 5 15 15 15 ABCD
8 Male 2 16.8 16.8 17.5 ABCD
9 Male 2 15.4 15.4 15 ABCD
Order of treatments: A = Prednisolone IV, B = placebo IV, C = Prednisolone PO, D =
placebo PO.
Housing and Feeding
The rooms were 20 m2 with raised platforms, toys and resting
spaces. During daytime, the dogs were let outside in a pen with a
doghouse. The dogs had access to a large exercise pen with grass
and tunnels once a week. Dogs were fed nutritionally complete
commercial feed (Hills pet nutrition, Langeskog, Denmark) twice
daily. Water was available ad libitum.
Experimental Design
Groups of dogs housed together were randomly assigned to
one of four treatments; active (prednisolone) per os (PO),
active intravenously (IV), placebo PO or placebo IV in a 4-way
crossover experiment. The order of treatments for each dog are
given in Table 1.
Treatments
For the active treatments, prednisolone-sodiumsuccinate
(Precortalon R© aquosum, Biocodex AB, Kista, Sweden) at a
concentration of 25 mg/mL was administered once IV and
prednisolone tablets (Prednisolon Pfizer, Pfizer AB, Sollentuna,
Sweden) once daily for ten consecutive days PO in the dogs’
morning meal. The prednisolone doses were 0.97–1.07 mg/kg
and precise dose for each dog are given in Table 1. For the
placebo treatments, saline (Natriumklorid Fresenius Kabi 9
mg/ml, Fresenius Kabi AB, Uppsala, Sweden) was used IV and a
morning meal without prednisolone tablets was used PO.
Sample Collection
During the IV-treatment, blood was sampled before drug
administration (0 h) and 0.33, 0.67, 1, 2, 3, 4, 6, 9, 12, 24,
28, 32, 36, 48, and 60 h after drug-administration. During PO-
treatments blood was sampled before drug-administration at
day 1 (0 h), 7 (144 h) and 10 (216 h). Additional blood was
sampled 1, 2, 4, 7, 10, 22, 26, 30, 34, and 72 h after the last drug
administration (217, 218, 220, 223, 226, 238, 242, 246, 250, and
288 h after the first dose). A schematic overview of the dosing and
sampling protocol is shown in Figure 1. EDTA-coated tubes were
used for all blood-samples. Blood for differential white blood cell
count was transferred to new tubes before the rest of the blood
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FIGURE 1 | Schematic overview of the dose (D) and sampling (filled diamonds) regimen after administration of 1 mg/kg prednisolone succinate and placebo
intravenously (IV, upper plot “A”) or ∼1 mg/kg prednisolone or placebo once daily per os (PO, lower plot “B”) for 10 days to nine beagle dogs in a cross-over study.
The magnification in the center show the 3 days following the last oral dose. (A) Dose and sampling regimen for IV administration. (B) Dose and sampling regimen for
PO administration.
was centrifuged at 2,100 g. The plasma was stored at −70◦C
pending prednisolone and cortisol analyses.
White Blood Cell Differential Count
Total and differential white blood cell count was analyzed
with canine settings with an ADVIA 2120 instrument with
Multi Species Software (Siemens Healthcare, Dublin Ireland, L-
00000062, Dec 20, 2018), a validated method more precise than
manual counts (14).
Analytical Method
The quantitative analyses of prednisolone and cortisol were
carried out with ultra-high performance liquid chromatography
– tandem mass spectrometry (UHPLC-MS/MS) at the National
Veterinary Institute (SVA), Uppsala, Sweden. The reference
compounds for prednisolone and cortisol and the internal
standards [2H8]-prednisolon and [
2H7]-hydrocortison were
purchased from Toronto Research Chemicals (North York, ON,
Canada). The sample preparation was performed as follows: to
100 µL of canine lithium heparinated plasma (study samples,
calibrators or quality control samples), 100 µL of internal
standard solution and 200 µL of trichloroacetic acid (20% v/v
in water) was added for protein precipitation. The samples
were then vortexed for 10min and centrifuged at 10,000 g for
10min. The supernatants were transferred to 96-well plates and
10 µL were injected into the UHPLC-MS/MS system consisting
of an Acquity UPLC coupled to a Xevo TQ-S micro tandem
quadrupole mass spectrometer equipped with an electrospray
ionization interface operating in the positive mode, all from
Waters Corp. (Milford, MA, USA). The analytical column was an
Acquity UPLCBEHC18 (length 100mm, inner diameter 2.1mm,
particle size 1.7µm) held at 65◦C. The mobile phase consisted
of (A) 10mM ammonium formate in water and (B) 0.1% formic
acid in acetonitrile. Gradient elution was used: initially 23% B for
3.0min, linear increase to 80% B for 0.5min, constant at 80%
B for 1.0min, linear decrease to 23% B for 0.1min, constant at
23% B for 0.9min. The flow-rate was set to 400 µL/min. The
electrospray parameters were: capillary voltage 0.50 kV and cone
voltage 35V. The desolvation and source block temperatures
were 500 and 150◦C, respectively. The desolvation gas flow-rate
was 1,000 L/h. The quantification was carried out in the Selected
Reaction Monitoring (SRM) mode with the collision cell filled
with argon at 1.3 × 10−5 mBar. The SRM transitions used were
m/z 361 → 147 for prednisolone (collision energy 25 eV) and
m/z 369→ 150 for [2H8]-prednisolone (collision energy 25 eV),
m/z 363→ 121 for cortisol (collision energy 25 eV) andm/z 369
→ 100 for [2H7]-hydrocortison. The dwell time was 0.082 s. The
calibration curves were constructed with the chromatographic
peak area ratio (analyte/internal standard) as a function of the
analyte concentration. Calibration and quality control samples
for prednisolone were prepared by spiking reference compound
to blank canine plasma. Calibration samples for cortisol were
prepared by spiking reference compound to water, since this
analyte is endogenous to the dog. Quality control samples of
cortisol were prepared both by spiking reference compound to
water and to canine plasma. The calibration functions were




In order to obtain values for the area under the curve
(AUC) to estimate the oral bioavailability of prednisolone,
the plasma concentration-time data were subjected to
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non-compartmental analyses using WinNonlin 4.0.1 (Certara,
St. Louis, Missouri, U.S.A). The PK data were then analyzed
by fitting a compartmental model using the non-linear mixed
effects (NLME) approach as implemented in the software
Monolix2018R2 (Antony, France: Lixoft SAS, 2018). Visual
inspection of diagnostic plots, the Akaike Information Criterion
(AIC) and the Bayesian Information Criterion (BIC) were used
to judge the best fit. Observations below the LOQ were treated as
censored, i.e., any positive value below 0.05 ng/mL. The model
parameters were the central (Vc) and peripheral (Vti) volumes
of distribution, plasma clearance (Cl) and inter-compartmental
distribution clearance (Cldi), where i denotes the number of
peripheral compartments needed to best describe the data. The
parameter-values obtained after IV-analysis were then fixed
so that the oral absorption rate constant (ka) and lag time in
absorption (tlag) could be estimated from the PO data. For the
PD analysis, the IV and PO PK models with parameter values
fixed to the values estimated in the first step were used to simulate
the prednisolone concentration-time course driving the PD-
response. A turnover model was fitted to the PD-data (cortisol,
lymphocyte- and neutrophil counts) obtained after both IV-
and PO-administration of prednisone and saline (placebo).
For cortisol, production was inhibited, for lymphocytes, loss
was stimulated and for neutrophils, loss was inhibited. The
model parameters were the maximum response (Imax/Emax), the
concentration at 50% of maximum response (IC50/EC50), the
sigmoidicity parameter (n), the baseline of the response (R0) and
the fractional elimination rate of the response (kout).
The statistical model for between subject variability (BSV) was
described by:
θi = θtv · exp(ηi) (1)
where θi is the value of the pharmacokinetic parameters in the
ith dog, θtv is the typical population value of the parameter
and ηi is the deviation from the corresponding population
value associated to the ith dog (15). The exponential model
assumes log-normal distribution of the parameters, i.e., that
the distribution of the etas (ηi) is normal in the log-domain,
with a mean of 0 and the standard deviation of the random
effects ω where η ≈ N[0,ω2]. The standard deviation of the
random effects reported by Monolix R© was then transformed to
a coefficient of variation (CV%) using Equation (2):
CV% =
√
exp(ω2)− 1 · 100 (2)






where var(ηr) is the variance of the random effects. When
shrinkage for eta were >30%, the random component was
not considered robustly estimated. Sex, weight, and age were
investigated as covariates. Impact on objective function values,
parameter BSV and Monolix internal statistical functions were
used in covariate evaluation.
FIGURE 2 | Overview of the pharmacokinetic and pharmacodynamics model.
(A) The plasma absorption and disposition model where Cgut, ka, Vc, Vt, Cl,
and Cld represent the drug disposed in the gut, the absorption rate constant
from the gut to the central compartment, central and peripheral volume of
distribution, clearance and inter-compartmental distribution parameter,
respectively. (B) The turnover model describing the prednisolone induced
changes in response (R). The plasma concentration (Cp) was used to “drive”
the drug mechanism function [I (Cp)] acting on the turnover rate of response
where kin(t), kout and R represent the turnover rate and the fractional turnover
rate. For cortisol production of response was inhibited, for lymphocytes loss
was stimulated and for neutrophils, loss of response was inhibited.
RESULTS
Analytical Method
The linear calibration ranges were 0.50–500 ng/mL for
prednisolone and 0.27–543 ng/mL for cortisol. The precision
(RSD%) was for prednisolone in the range of 1.6–11% and for
cortisol 1.3–10%. The accuracy was for prednisolone in the range
of 87–108% and for cortisol 87–104%.
Model Evaluation
A two-compartment model was judged to be the best fit for the
prednisolone PK-data. The between subject variability could be
robustly estimated for all the PK parameters and for the potency
(IC50), efficacy (Imax) and the base line of response (R0) in the
PD model. None of the covariates improved the model and these
were therefore discarded. A schematic overview of the PK/PD




After IV administration of 1 mg/kg prednisolone, plasma
prednisolone concentrations decreased rapidly and observed
concentrations were below LOQ (0.5 ng/mL) after 24 h in
all dogs. Twelve hours after prednisolone administration,
plasma prednisolone concentration ranged between 0.78 and
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FIGURE 3 | Observed (symbols) and model predicted (lines) prednisolone plasma concentration-time courses following administration of 1 mg/kg prednisolone
succinate intravenously (left plot A) and after the last dose (216 h after first dose) of approximately 1 mg/kg for 10 consecutive daily oral doses (right plot B) to 9 beagle
dogs. Twenty four hours after IV-administration or 24 h after the last dose per os (240 h after the first dose) prednisolone plasma concentration was below the lower
limit of quantification (0.5 ng/mL) in all dogs.
4.1 ng/mL (Figure 3). During oral treatment over a 10-day
period, pre-administration prednisolone plasma concentrations
only exceeded the LOQ once (0.79 ng/mL, day 7) in one dog.
After the last dose, peak plasma concentrations were observed
in eight of the dogs within 4 h after administration and one
dog showing slower absorption and a peak concentration 7 h
after administration (Figure 3). Ten hours after the last dose,
plasma prednisolone concentrations ranged between 2.3 and
15.2 ng/mL in eight dogs. In one dog plasma prednisolone
concentration was 42.6 ng/ml 10 h after last drug administration.
This dog also showed the slowest absorption. At 22 h after
last prednisolone administration plasma concentrations were
below the LOQ in all dogs. Relative to plasma prednisolone
exposure after IV administration, the PO bioavailability was
median (range) 108% (87–118). The PO bioavailability could be
biased by slow hydrolyses of the succinate ester and is hence a
function of the bioavailability following IV administration (see
section Discussion).
A two-compartment pharmacokinetic model fit the
experimental prednisolone data collected after IV administration
of prednisolone succinate well (Figure 3). The parameters were
estimated with good precision (CV 4–19%). The model was
then fitted to experimental prednisolone data collected after PO
administration, but parameters could not be robustly estimated,
most likely due to masking of the distribution phase by the
absorption. The disposition parameters were therefore fixed
so that only the absorption parameters needed to be estimated
from the PO data. These parameters were estimated with
acceptable to poor precision (CV 30–66%). The pharmacokinetic
parameters and the corresponding BSV are shown in
Table 2.
Neutrophil, Lymphocyte, and Cortisol
Response
Placebo treatment observations suggest that neutrophils and
lymphocytes had limited variability compared to cortisol which
was more variable both within and between animals (Figures 4–
6). Exposure to prednisolone increased neutrophil counts
(Figure 4) and decreased both lymphocyte counts (Figure 5) and
cortisol plasma concentrations (Figure 6). All three response
TABLE 2 | Model estimated pharmacokinetic typical values, their corresponding
relative standard deviation (CV%) and the between subject variation (BSV) and
secondary pharmacokinetic parameters after intravenous (IV) administration of 1
mg/kg prednisolone succinate and administration of ∼1 mg/kg prednisolone per
os (PO).
Model parameters Unit Typical value (CV%) BSV (%)
IV
Vc/FIV mL/kg 2,300 (3.8) 10.7
Vt/FIV mL/kg 600 (5.7) 16.0
Cl/FIV mL/h·kg 1,370 (4.5) 13.4
Cld mL/h·kg 530 (19.2) 58.2
PO
ka h
−1 2.52 (65.9) 194.2
tlag h 0.69 (30.1) 60.9
Secondary parameters Unit
α h−1 1.3 –
β h−1 0.4 –
t1/2α h 0.5 –
t1/2β h 1.7 –
Vc, Vt, Cl, Cld ka, and tlag represent central and peripheral volumes of distribution,
clearance and inter-compartmental distribution parameter, the absorption rate constant
from the gut to the central compartment and the lag-time, respectively. α, β, t1/2α ,
and t1/2β represent the rate constant of the initial and terminal phase and the half-
lives of the initial and terminal phase, respectively. FIV indicate that the parameter values
may be confounded of unknown bioavailability of prednisolone after IV administration of
prednisolone succinate in dogs IV (see section Discussion).
courses demonstrated an onset of response within 3 h, maximum
response within 10 h and were estimated to be back to base line
at 24–36 h. The turnover model described the observed data
well and generated model parameters with acceptable to good
precision. Pharmacodynamic parameter values, their precision
and BSV are shown in Table 3.
There were two missing values in neutrophil and lymphocyte
response because one sample had clotted and one sample was
lost because of technical problems. The missing values were both
from active IV treatment and from two different dogs, 32 and 48 h
after administration, respectively.
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FIGURE 4 | Observed (symbols) and model predicted (lines) neutrophil count-time courses following intravenous administration (left plots) of 1 mg/kg prednisolone
succinate (1A) or saline (2A) and after the last oral (right plots) dose (216 h after first dose) of ∼1 mg/kg for 10 consecutive daily doses orally (1B) or placebo (2B) to 9
beagle dogs.
FIGURE 5 | Observed (symbols) and model predicted (lines) lymphocyte count-time courses following intravenous administration (left plots) of 1 mg/kg prednisolone
succinate (1A) or saline (2A) and after the last oral (right plots) dose (216 h after first dose) of ∼1 mg/kg for 10 consecutive daily doses orally (1B) or placebo (2B) to 9
beagle dogs.
DISCUSSION
The dosage regimen (dose and dose interval) is one corner
stone in pharmacological therapy. The PK (absorption,
distribution, and elimination) of a drug combined with
toxicology data and the turnover of the PD response decide
the therapeutic window and the dosage regimen. This study
describes the plasma exposure, PK and PD of prednisolone in
dogs using neutrophil and lymphocyte cell counts as response
to prednisolone exposure which provide additional evidence
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FIGURE 6 | Observed (symbols) and model predicted (lines) cortisol plasma concentration-time courses following intravenous administration (left plots) of 1 mg/kg
prednisolone succinate (1A) or saline (2A) and after the last oral (right plots) dose (216 h after first dose) of ∼1 mg/kg for 10 consecutive daily doses orally (1B) or
placebo (2B) to 9 beagle dogs.
TABLE 3 | Model estimated pharmacodynamics typical values (t.v.), their corresponding relative standard deviation (CV%) and between subject variation (BSV) after
intravenous administration of 1 mg/kg prednisolone succinate and ∼1 mg/kg prednisolone per os.
Parameter Unit Neutrophils Lymphocytes Cortisol
t.v. (CV%) BSV (%) t.v. (CV%) BSV (%) t.v. (CV%) BSV (%)
IC50/EC50 ng/mL 10 (36.9) 90.3 22.5 (32.6) 52.3 0.04 (50.1) 197.3
Imax/Emax – 1 (5.5) 5.0 1 (14.4) 35.0 1 (1.6) 4.8
n – 0.66 (2.2) – 1 (0.07) – 1 (0.02) –
R0 10
9/L1 ng/mL2 4.81 (7.7) 23.1 1.91 (10.8) 33.4 102 (9.8) 28.2
kout 1/h 0.382 (4.2) – 0.232 (3.93) – 2.4 (4.4) –
IC50/EC50, Imax/Emax , n, R0, and kout are the potency value, efficacy value, sigmoidicity parameter, baseline of response, and elimination-rate constant of response, respectively.
1Unit
for Neutrophil/Lymphocyte cell counts. 2Unit for cortisol concentration.
and input to future studies using clinical outcome or more
relevant inflammatory/immunosuppressive biomarkers to
optimize pharmacotherapy.
Prednisolone exposure after 1 mg/kg caused increased
neutrophil numbers and decreased lymphocyte numbers
that returned to baseline within 24 h from prednisolone
administration. The return to baseline was due to the short half-
life of prednisolone in dogs, resulting in plasma concentrations
falling below effective concentrations values within hours, and
the relatively rapid turnover and migration of these white
blood cells (16–18). The 1 mg/kg dose is within the clinically
established dose-range (0.5–4mg/kg) for prednisolone. However,
if treatment is to be continued for longer periods of time, the
lowest effective dose should be used to minimize adverse effects.
A dose of 0.5 mg/kg every second day is considered clinically
effective in some cases. Considering the short terminal half-life
(1.7 h) and the high IC50-values (10–22.5 ng/mL), concentrations
above those IC50-values were maintained <24 h in plasma
following oral administration of 1 mg/kg prednisolone to
beagle dogs.
It is established that the clinical efficacy and half-life of
response of corticosteroids is longer than the pharmacokinetic
half-life for glucocorticoids (19). This is likely due to modulation
of the transcription of genes encoding for inflammatory
modulators that have a slower turnover than the biomarkers
measured in this study. The immunosuppressive (and anti-
inflammatory) responses to glucocorticoids are numerous
(20). For instance, glucocorticoids induce synthesis of the
anti-inflammatory protein Annexin A1 (21). Annexin A1 is
stored in the cytoplasm and must be degraded before its
effect disappears. Possibly prednisolone affects some of these
biomarkers with a higher potency increasing the time in the
therapeutic window. Both of these factors could explain the
clinical effect that is longer than the duration of response
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reported here. In addition, low prednisolone doses are usually
used against mild and chronic symptoms. Possibly, the
short exposure inhibits the stimulatory processes within the
turnover of low-grade inflammatory processes and thereby
hinders development of clinical signs which could explain
why the dose 0.5 mg/kg every second day can be clinically
efficient. However, this hypothesis remains to be verified in
future studies.
The previously presented pharmacokinetic parameter
estimates for clearance and bioavailability are lower than their
corresponding typical values in this study (1–3). Prednisolone is
poorly soluble in water so esters (e.g., prednisolone phosphate
and prednisolone succinate) are formulated and used for IV
administration. Both prednisone phosphate and prednisolone
succinate are prodrugs that need to be bio-converted (i.e.,
hydrolysed) before their active compound prednisolone becomes
systemically available. Prednisolone phosphate is rapidly
converted to prednisolone in dogs (22) which was interpreted
as the entire prednisolone dose was made systemically available.
The succinate ester has also been shown to be rapidly hydrolysed
in vivo in rabbits but not in vitro in plasma or whole blood
indicating that the active compound probably becomes
systemically available due to organ clearance (23). In dogs,
however, the fraction of the dose methylprednisolone made
systemically available was 43% after IV administration of
methylprednisolone succinate (24). Toutain et al. (24) argues
that this species difference is due to a genetic predisposition
for over-expression of carboxylases in the rabbit strain used
in (23). If the results in (24) is also true for prednisolone
succinate the results from the PK analyses presented here
should be interpreted with great caution for other types of
prednisolone esters. The PK-part of the study assumed that the
dose administered IV was made 100% systemically available and
used for estimation of both bioavailability and clearance. The
PK model was successfully fitted to experimental data with good
to acceptable precision and described the concentration-time
course adequately. The potentially low systemic availability
of prednisolone after IV administration of prednisolone
warrants further attention in relation to PK-model output. If
the bioavailability of prednisolone in dogs is similar to that
of methylprednisolone in (24), it could explain the difference
in bioavailability and mean clearance values reported after IV
administration of prednisolone phosphate (1–3). It should be
noted that the range of clearance values within the previously
studied populations in (1–3) overlap the individual parameter
range for clearance in this study. It cannot be excluded that the
differences in results could be due to between study variability.
Nevertheless, the fraction prednisolone made systemically
available after IV administration of prednisolone phosphate and
prednisolone succinate warrants future attention. Until then,
the pharmacokinetic model parameter values reported in this
study should be considered specific for the succinate formulation
and only be extrapolated to formulations containing other salts
cautiously. The terminal half-life, which is an important clinical
parameter since it is used for estimation of dosage interval,
depends on the rate of elimination which in turn shapes the
slope of the terminal phase of the concentration-time course.
The model was adequately fitted to experimental observations,
mimicked the slope and therefore the half-life should be
considered reliable. The half-lives were also confirmed by visual
inspection of experimental data.
The major reason to perform a PK analyses on prednisolone
data was to derive a PK-profile that then later was used to “drive”
the PD-model. The predicted time-courses fitted experimental
data well and PK-analyses were functional in this aspect (data
not shown). Consequently, the PD-parameters for increased
neutrophil numbers, decreased lymphocyte numbers and cortisol
suppression deserve attention. These are known glucocorticoid
responses (25–28). In other species white blood cell counts and
cortisol suppression has also been used to derive quantitative PD-
data and estimate the magnitude and duration of glucocorticoid
response (12, 29, 30). The pharmacodynamics model was fitted
to experimental data, the predicted time courses mimicked data
well and the model parameters were estimated with good to
acceptable precision. In order to maintain prednisolone plasma
concentration above the potency value the entire dosage interval,
an increase of the daily dose 1 mg/kg and more frequent
dosing is necessary. If change in white blood cell counts are
suitable surrogate markers for immunosuppressive responses
to prednisolone, these results strengthen the empirical initial
prednisolone daily dose for immunosuppression (2–4 mg/kg).
It is, however, known that individual patients respond to
lower doses (31, 32). Doses should, therefore, be individually
tapered down to achieve the lowest possible clinically effective
prednisolone dose for a specific patient. Hence, the results
presented in this study are more useful as input in the design of
clinical studies than for individual dose-recommendations. For
example, Monte Carlo simulations can be performed with the
model to predict the probability of favorable clinical outcomes
for a given dosage regimen in a target population (33). These
predictions can then be compared with experimental outcomes
as part of the learn-confirm cycle of developing safe and effective
veterinary therapies. It should also be noted that this study used
Beagle dogs only. Inter-breed differences in PK and PD might
occur (34) and the results from this study should be interpreted
with this in mind. In the future, this model can be validated and
refined with data from studies in other breeds to quantify any
possible variability in PK and PD parameter values.
The BSV for the PK-parameters was low for parameters
estimated with good precision. The parameters ka and tlag both
had low precision and high BSV, which most probably was due to
limited experimental data in the absorption phase. However, also
the potency value (IC50/EC50-value) BSV was quite substantial in
this study with greatest values for cortisol response. It is known
that PD usually show larger variability between individuals than
PK (35). To the best of our knowledge no BSV-values are
published for glucocorticoid responses in dogs. In the horse,
the BSV for cortisol suppression after dexamethasone exposure
was up to 80% (36, 37), which is comparable with the BSV
for neutrophil and lymphocyte IC50–values but lower than the
variability on cortisol response potency in this study. The reason
behind this variation is not fully known but sex and age has
been shown to be sources of variation in cortisol concentration
in dogs (38, 39). In the present study, age and sex were evaluated
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as covariates but could not explain the large BSV. Possibly, a
larger study population would increase the chances in explaining
BSV variation due to age and sex. Differences between species,
substances and study design could provide additional possible
explanations to the relatively high BSV.
In conclusion: Prednisolone is cleared rapidly which results
in a short terminal half-life. After PO administration, maximum
concentrations were observed within 1 h in most of the dogs.
The administered dose (1 mg/kg) caused increased neutrophil
numbers and decreased lymphocyte numbers but did not
result in effective plasma concentration over the entire dosage
interval of 24 h. However, glucocorticoids have a wide range
of responses and e.g., anti-inflammatory responses due to
altered gene transcription might have longer duration of effects.
Future studies on the anti-inflammatory potency of prednisolone
together with data presented here could possibly optimize future
dosage recommendations in dogs.
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